HLA-G14bp ins/del polymorphism and post-transplant weight gain in kidney transplantation: potential implications beyond tolerance

Table 1 Demographic and clinical characteristics of kidney transplant recipients (n = 173)

Gender (n, %)	M: 117 (67.6%) F: 56 (32.3%)
Age at transplant (years, mean ± SD)	46.77 ± 10.60 (range 24–68)
Dialysis mode (%)	19% peritoneal, 81% hemodialysis
Time on dialysis (years, mean ± SD)	2.81 ± 2.97 (range < 1–26)
Immunosuppressive therapy:
• Calcineurin inhibitors (CsA or TAC), steroids, purine synthesis inhibitors (%)	84%
• mTOR inhibitors, steroids, purine synthesis inhibitors (%)	16%
Pre-transplant impaired/diabetic fasting blood glucose^a(%)	13%
Cold ischemia time (hours, mean ± SD)	11.45 ± 3.31 (range 4.2–21.6)
Recipients with acute rejection episodes (n, %)	24 (13.9%)
Graft loss^b(n, %)	4 (2.3%)
Primary nephropathy
Glomerulonephritis^c	73 (42%)
Polycystic kidney disease	33 (19%)
Nephroangiosclerosis	6 (4%)
Hypertensive/vascular nephropathies	19 (11%)
Chronic pyelonephritis	8 (5%)
Not determined	16 (9%)
Other nephropathies^d	18 (10%)

^afasting plasma glucose: impaired: 111–125 mg/dl; diabetic: > 125 mg/dl (WHO)
^bfour cases of graft loss during the 5-years follow up (over 3 years post-transplant)
^cchronic, membranous, focal glomerulosclerosis, rapidly progressive, LES, Goodpasture, IRC post-partum, diabetic, Alport syndrome, IgA nephropathy
^dcongenital, amyloid, neoplastic, post-traumatic, obstructive, hemolytic-uremic syndrome, contracted kidney, interstitial nephropathy

ISSN: 1471-2369